{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T13:49:04Z","timestamp":1776001744248,"version":"3.50.1"},"reference-count":36,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2018,3,25]],"date-time":"2018-03-25T00:00:00Z","timestamp":1521936000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>This analysis assessed the efficacy and safety of alirocumab, a proprotein convertase subtilisin\/kexin type 9 inhibitor, in patients with or without metabolic syndrome (MetS) using pooled data from 10 phase 3 ODYSSEY trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>Data from 4983 randomized patients (1940 with MetS; 1642 with diabetes excluded) were assessed in subgroups by MetS status. Efficacy data were analysed in 4 pools per study design: 2 placebo\u2010controlled pools (1 using alirocumab 150 mg every 2 weeks [Q2W], 1 using 75\/150 mg Q2W) with background statin, and 2 ezetimibe\u2010controlled pools (both alirocumab 75\/150 mg Q2W), 1 with and 1 without background statin. Alirocumab 75\/150 mg indicates possible dose increase from 75 to 150 mg at Week 12 based on Week 8 LDL\u2010C.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>LDL\u2010C percentage reduction from baseline at Week 24 with alirocumab was 63.9% (MetS) and 56.8% (non\u2010MetS) in the pool of alirocumab 150 mg Q2W, and 42.2% to 52.2% (MetS) and 45.0% to 52.6% (non\u2010MetS) in 3 pools using 75\/150 mg Q2W. Levels of other lipid and lipoprotein parameters were also improved with alirocumab treatment, including apolipoprotein B, non\u2010high\u2010density lipoprotein cholesterol (non\u2010HDL\u2010C), lipoprotein(a) and HDL\u2010C. Overall, the percentage change at Week 24 in LDL\u2010C and other lipids and lipoproteins did not vary by MetS status. Adverse event rates were generally similar between treatment groups, regardless of MetS status; injection\u2010site reactions occurred more frequently in alirocumab vs control groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Across study pools, alirocumab\u2010associated reductions in LDL\u2010C, apolipoprotein B, and non\u2010HDL\u2010C were significant vs control, and did not vary by MetS status.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.13273","type":"journal-article","created":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T06:32:40Z","timestamp":1519885960000},"page":"1632-1641","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials"],"prefix":"10.1111","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4821-0117","authenticated-orcid":false,"given":"Robert R.","family":"Henry","sequence":"first","affiliation":[{"name":"Department of Medicine University of California San Diego  San Diego California"},{"name":"Center for Metabolic Research Veterans Affairs, San Diego Healthcare System  San Diego California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"M\u00fcller\u2010Wieland","sequence":"additional","affiliation":[{"name":"Department of Medicine I University Hospital Aachen  Aachen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pam R.","family":"Taub","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Medicine University of California  San Diego California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maja","family":"Bujas\u2010Bobanovic","sequence":"additional","affiliation":[{"name":"Sanofi  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Louie","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc.  Tarrytown New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexia","family":"Letierce","sequence":"additional","affiliation":[{"name":"Sanofi, Biostatistics and Programming  Chilly\u2010Mazarin France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry N.","family":"Ginsberg","sequence":"additional","affiliation":[{"name":"Columbia University  New York New York"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,3,25]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.192644"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/943162"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2015.08.002"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2015.02.003"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.05.034"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.52.5.1210"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-015-0552-3"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2012.06.052"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2015.04.810"},{"key":"e_1_2_6_11_1","unstructured":"Sanofi. Praluent prescribing information (USA).http:\/\/products.sanofi.us\/praluent\/praluent.pdf. Accessed April 25 2017."},{"key":"e_1_2_6_12_1","unstructured":"Sanofi. Praluent summary of product characteristics (EC).http:\/\/ec.europa.eu\/health\/documents\/community\u2010register\/2015\/20150923132812\/anx_132812_en.pdf. Accessed April 25 2017."},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-016-0939-0"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v8.i7.311"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.111.241919"},{"key":"e_1_2_6_16_1","first-page":"2996","article-title":"ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia","volume":"36","author":"Kastelein JJ","year":"2015","journal-title":"Eur Heart J"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1520"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv028"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2015.03.004"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501031"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2015.11.010"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2014.06.049"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2015.08.006"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-016-6685-y"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2013.12.005"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69292-1"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.298.3.299"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.025253"},{"key":"e_1_2_6_29_1","unstructured":"Santarus. Fenoglide prescribing information (USA).https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/022118s005lbl.pdf. Accessed April 27 2017."},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61965-6"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.860"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61190-8"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1604304"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw292"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12909"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13450"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30313-3"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.13273","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.13273","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.13273","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.13273","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T03:04:28Z","timestamp":1761879868000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.13273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,25]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["10.1111\/dom.13273"],"URL":"https:\/\/doi.org\/10.1111\/dom.13273","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,25]]},"assertion":[{"value":"2017-11-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-02-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}